CCL

Összesen 1 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM062009
035-os BibID:(WoS)000369191800039 (Scopus)84950153946
Első szerző:Goyard, David
Cím:Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition / David Goyard, Bálint Kónya, Aikaterini S. Chajistamatiou, Evangelia D. Chrysina, Jérémy Leroy, Sophie Balzarin, Michel Tournier, Didier Tousch, Pierre Petit, Cédric Duret, Patrick Maurel, László Somsák, Tibor Docsa, Pál Gergely, Jean-Pierre Praly, Jacqueline Azay-Milhau, Sébastien Vidal
Dátum:2016
ISSN:0223-5234 1768-3254
Megjegyzések:Glycogen phosphorylase (GP) is a target for the treatment of hyperglycaemia in the context of type 2 diabetes. This enzyme is responsible for the depolymerization of glycogen into glucose thereby affecting the levels of glucose in the blood stream. Twelve new d-glucopyranosylidene-spiro-isoxazolines have been prepared from O-peracylated exo-D-glucals by regio- and stereoselective 1,3-dipolar cycloaddition of nitrile oxides generated in situ by treatment of the corresponding oximes with bleach. This mild and direct procedure appeared to be applicable to a broad range of substrates. The corresponding O-unprotected spiro-isoxazolines were evaluated as glycogen phosphorylase (GP) inhibitors and exhibited IC50 values ranging from 1 to 800 ?M. Selected inhibitors were further evaluated in vitro using rat and human hepatocytes and exhibited significant inhibitory properties in the primary cell culture. Interestingly, when tested with human hepatocytes, the tetra-O-acetylated spiro-isoxazoline bearing a 2-naphthyl residue showed a much lower IC50 value (2.5 ?M), compared to that of the O-unprotected analog (19.95 ?M). The most promising compounds were investigated in Zucker fa/fa rat model in acute and sub-chronic assays and decreased hepatic glucose production, which is known to be elevated in type 2 diabetes. This indicates that glucose-based spiro-isoxazolines can be considered as anti-hyperglycemic agents in the context of type 2 diabetes.
Tárgyszavak:Természettudományok Kémiai tudományok Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Carbohydrates
Spiro-isoxazolines
Glycogen phosphorylase inhibitors
Hepatocytes
Zucker rats
Hepatic glucose production
Type 2 diabetes
Megjelenés:European Journal of Medicinal Chemistry. - 108 (2016), p. 444-454. -
További szerzők:Kónya Bálint (1984-) (vegyész) Chajistamatiou, Aikaterini S. Chrysina, Evangelia D. Leroy, Jérémy Balzarin, Sophie Tournier, Michel Tousch, Didier Petit, Pierre Duret, Cédric Maurel, Patrick Somsák László (1954-) (vegyész) Docsa Tibor (1975-) (vegyész, biokémikus) Gergely Pál (1947-) (biokémikus) Praly, Jean-Pierre Azay-Milhau, Jacqueline Vidal, Sébastien
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1